Skip to content
Clinical Trials – home

The Rotterdam Eye Hospital

Research site

The Netherlands Schiedamse Vest 180, 3011 BH Rotterdam, The Netherlands

  • 5 trials recruiting
  • Dry age-related macular degeneration · Neovascular age-related macular degeneration · Retinitis pigmentosa
  • Adults and children

About Specializations

The Rotterdam Eye Hospital in Rotterdam, The Netherlands specialises in clinical trials of conditions such as Dry age-related macular degeneration, Neovascular age-related macular degeneration, Retinitis pigmentosa, Central serous chorioretinopathy, and other specialisations. This site conducts important research.

Main research areas of the site

Eye Diseases

The Rotterdam Eye Hospital is active in ophthalmology research focused on a range of vision-threatening conditions. Current studies examine exudative age-related macular degeneration, neovascular age-related macular degeneration, geographic atrophy, central serous chorioretinopathy, and persistent corneal epithelial defect, with the goal of improving treatment effectiveness and patient outcomes.

  • Research includes testing new approaches for retinal disease, evaluating treatment combinations, and assessing therapies that may better preserve vision.
  • Studies also look at healing support for corneal surface disease and symptom control in chronic eye conditions.
  • The site supports clinical research aimed at both short-term improvement and longer-term disease management.

These trials reflect a strong focus on retina, macular, and corneal disorders, with an emphasis on finding safer and more effective care options.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Research at this site also covers inherited eye disease, especially conditions that affect vision from an early age or progress over time. Key studies involve retinitis pigmentosa and Stargardt disease, focusing on whether emerging therapies can slow disease progression and support retinal function.

  • Investigations are centered on inherited retinal disorders linked to genetic causes and long-term vision loss.
  • The research aims to evaluate whether new treatments can improve disease control and protect remaining sight.
  • These studies add an important genetic ophthalmology dimension to the hospital’s trial portfolio.

The work at Rotterdams Oogheelkundig Instituut highlights efforts to advance care for patients with rare, hereditary conditions where treatment options remain limited.

Specialized Vision and Ocular Surface Research

Several trials at the Rotterdam Eye Hospital focus on specific eye conditions such as acquired blepharoptosis and persistent corneal epithelial defect. These studies are designed to test new therapies that may improve eyelid function or support corneal healing more effectively than current care.

  • Research in this area includes evaluating treatments for drooping eyelids that can affect vision and daily comfort.
  • Ocular surface studies are examining ways to promote complete healing in hard-to-treat corneal defects.
  • The site’s work combines symptom relief, visual function, and tissue repair as key research goals.

Together, these studies show a broad commitment to improving both common and rare eye disorders through clinical investigation.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Schiedamse Vest 1803011 BH RotterdamThe Netherlands
Recruiting now
5 trials
Conditions studied
8

More sites in RotterdamThe Netherlands

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

11 clinical trials

Cenegermin Eye Drops for Persistent Corneal Epithelial Defect in Patients with Persistent Corneal Epithelial Defect

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

A study to evaluate the safety and effectiveness of AAVB-039 in patients with Stargardt disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Sponsor:Aavantgarde Bio S.r.l.

Study on the Effects of Prednisolone Acetate and Placebo Eye Drops for Patients with Chronic Central Serous Chorioretinopathy

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dextran 70
  • Sponsor:Radboud universitair medisch centrum Stichting

Study on Long-term Safety of JNJ-81201887 for Patients with Geographic Atrophy Due to Age-related Macular Degeneration

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Janssen Cilag International

Study on Vitrectomy, Alteplase, and Aflibercept for Patients with Wet Age-Related Macular Degeneration and Submacular Hemorrhage

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:King's College Hospital NHS Foundation Trust

Retinitis pigmentosa

Not yet recruiting

Study on the Effectiveness and Safety of Ultevursen for Patients with Retinitis Pigmentosa Due to USH2A Gene Mutations

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ultevursen
  • Sponsor:Laboratoires Thea

Eyelid ptosis

Not recruiting

Study on the Effectiveness and Safety of Oxymetazoline Hydrochloride Eye Drops for Adults with Acquired Blepharoptosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Oxymetazoline Hydrochloride
  • Sponsor:Santen

Retinitis pigmentosa

Not recruiting

Study of ultevursen treatment in patients with retinitis pigmentosa caused by mutations in USH2A gene exon 13

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ultevursen
  • Sponsor:Laboratoires Thea

Study of OPT-302 and Aflibercept for Patients with Wet Age-related Macular Degeneration

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Opthea Limited

Macular oedema

Not recruiting

Study on the Effects of RO7200220 for Adults and Children with Uveitic Macular Edema

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Humanised IgG2 monoclonal antibody against INTERLEUKIN-6
  • Sponsor:F. Hoffmann-La Roche AG

Study on JNJ-81201887 for Treating Geographic Atrophy in Age-related Macular Degeneration Patients

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Janssen Cilag International
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.